INTELLIGENT BIO SOLUTIONS IN
INBSNASDAQTrading Snapshot
- Day Range
- $1.62 – $1.68
- 52-Week Range
- $1.52 – $24.90
- Volume
- $1.69B
- Avg Volume
- $1.55B
- Shares Outstanding
- 2.4M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-9.66
- Dividend Yield
- —
- Dilution (1yr)
- +205.6%
Why Investors Own INBS
- ✓High-growth profile — revenue up +14.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INTELLIGENT BIO SOLUTIONS IN
INBS
StockOtter · stockotter.spaceAbout INTELLIGENT BIO SOLUTIONS IN
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript
Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S. Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today anno
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening Sys
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules
$5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System $5 Million Upfront at Closing and $5 Million Tranche
BlackRock Inc. Invests $149.96 Million in Intelligent Bio Solutions Inc. $INBS
BlackRock Inc. purchased a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ: INBS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund